
    
      Primary Effectiveness Endpoint: Typical and atypical GERD symptom elimination (scores ≤ 2 to
      each question) or clinically significant improvement (≥ 50% reduction in total scores) at
      6-month follow-up compared to baseline.

      Secondary Effectiveness Endpoints: GERD symptom elimination or clinically significant
      improvement at 12-month follow-up, 24-month follow-up and 36-month follow-up; complete
      discontinuation of PPIs; normalization of esophageal acid exposure; significant reduction in
      reflux episodes; healing of reflux esophagitis; reduction of hiatal hernia; safety supported
      by low incidence of serious adverse events.
    
  